Single dose NTBC-treatment of hereditary tyrosinemia type I

Journal of Inherited Metabolic Disease

Volumn 35, Issue 5, 2012, Pages 831-836

  Schlune, A ^a   Thimm, E ^a   Herebian, D ^a   Spiekerkoetter, U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITISINONE; SUCCINYLACETONE;

ARTICLE; CHILD; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; FAMILIAL DISEASE; FEMALE; HEREDITARY TYROSINEMIA TYPE 1; HUMAN; INFANT; MALE; METABOLIC REGULATION; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE DRUG DOSE; TYROSINEMIA;

CYCLOHEXANONES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOATES; HUMANS; INFANT; INFANT, NEWBORN; MALE; NITROBENZOATES; TYROSINEMIAS;

EID: 84866736294     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9450-9     Document Type: Article

References (20)

1. Chapkrani A, Holme E (2006) Disorders of tyrosine metabolism. In: Fernandes J, Saudubray JM, Van Den Berghe G, Walter JH (eds) Inborn metabolic diseases, 4th edn. Springer, Berlin, pp 233-243
2. D'Eufemia P, Celli M, Tetti M et al (2011) Tyrosinemia type I: longterm outcome in a patient treated with doses of NTBC lower than recommended. Eur J Pediatr 170:819
3. El-Karaksy H, Rashed M, El-Sayed R et al (2010) NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr 169:689-693
4. Hall MG, Wilks MF, McLean Provan Wet al (2001) Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3- cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol 52:169-177
5. Herebian D, Spiekerkötter U, Lamshöft M et al (2009) Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1,3-cyclohexanedione) in plasma of tyrosinemia type 1 patients. J Chromatogr B 877:1453-1459
6. Holme E (2006) Disorders of tyrosine degradation. In: Blau N, Leonard J, Hoffmann GF, Clarke JTR (eds) Physicians Guide to the Treatment and Follow-Up of Metabolic Diseases. Springer, Berlin, pp 49-56
7. Holme E, Lindstedt S (1995) Diagnosis and management of tyrosinemia type 1. Curr Opin Pediatr 7:726-732
8. Holme E, Lindstedt S (1998) Tyrosinemia type 1 and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 21:507-517
9. Holme E, Lindstedt S (2000) Nontransplant treatment of tyrosinemia. Clin Liver Dis 4:805-814
10. Jorquera R, Tanguay RM (2001) Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 10:1741-1752
11. Joshi SN, Venugopalan P (2004) Experience with NTBC therapy in hereditary tyrosinemia type 1: an alternative to liver transplantation. Anal Trop Paediatr 24:1741-1752
12. Masurel-Paulet A, Poggi-Bach J, Rolland MO et al (2008) NTBC treatment in tyrosinaemia type I: Long-term outcome in French patients. J Inherit Metab Dis 31:81-87
13. Mitchell G, Grompe M, Lambert M et al (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 1777-1805
14. Orfadin [EPAR product information]. European Medicines Agency, London; Retrieved from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000555/WC500049195.pdf. Accessed Oct 31, 2011.
15. Orfadin [package insert]. Swedish Orphan Biovitrium International AB, Sweden; September 2010. Retrieved from http://orfadin.com/orfadin-pkg-insert. pdf. Accessed 31 Oct 2011
16. Prieto JA, Andrade F, Lage L et al (2011) Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography-tandem mass spectrometry. Study of the stability of the samples at different temperatures. J Chromatogr B. doi:10.1016/j.jchromb.2011.01.31
17. Russo P, O'Regan S (1990) Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet 47:317-324
18. Sander J, Janzen N, Terhardt M et al (2011) Monitoring tyrosinemia type I: Blood spot test for nitisinone (NTBC). Clin Chim Acta 412:134-138
19. Schlump JU, Perot C, Ketteler K et al (2008) Severe neurological crisis in a patient with hereditary tyrosinemia type I after interruption of NTBC. J Inherit Metab Dis, published online.
20. Thimm E, Herebian D, Assmann B et al (2011) Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. Mol Genet Metab 102:122-125